Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. News
  7. Summary
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

European ADRs Move Sharply Lower in Monday Trading

09/20/2021 | 11:12am EDT


ę MT Newswires 2021
All news about ERYTECH PHARMA S.A.
10/11European ADRs Move Higher in Monday Trading
MT
10/05AFTER HOURS WATCH LIST SCORECARD : Agfy, eryp, cmtl,
MT
10/05ERYTECH PHARMA S A : Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator S..
PU
10/05ERYTECH PHARMA S A : Announces maximum tolerated dose declared in a phase 1 investigator s..
AQ
10/04ERYTECH PHARMA S A : Says Early Trial of Lead Therapy Showed 'Encouraging Clinical Activit..
MT
10/04MT NEWSWIRES AFTER HOURS WATCH LIST : Agfy, eryp, cmtl
MT
10/04ERYTECH PHARMA S A : Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator S..
AQ
10/04ERYTECH Pharma S.A. Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator..
CI
09/28ERYTECH PHARMA S A : to Participate in the HealthTech Innovation Days (HTID) by France Bio..
AQ
09/22ERYTECH PHARMA S A : Announces the Availability of its Half-Year Financial Report 2021
AQ
More news
Financials
Sales 2021 9,79 M 11,4 M 11,4 M
Net income 2021 -65,1 M -75,5 M -75,5 M
Net Debt 2021 16,1 M 18,7 M 18,7 M
P/E ratio 2021 -1,35x
Yield 2021 -
Capitalization 147 M 171 M 171 M
EV / Sales 2021 16,7x
EV / Sales 2022 4,25x
Nbr of Employees 196
Free-Float 67,5%
Chart ERYTECH PHARMA S.A.
Duration : Period :
ERYTECH Pharma S.A. Technical Analysis Chart | ERYP | FR0011471135 | MarketScreener
Technical analysis trends ERYTECH PHARMA S.A.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 5,27 €
Average target price 14,50 €
Spread / Average Target 175%
EPS Revisions
Managers and Directors
Gil Beyen Chief Executive Officer & Director
Eric Soyer Chief Operating & Financial Officer
Jean-Paul Kress Chairman
Iman El-Hariry Chief Medical Officer
Stewart Craig Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
ERYTECH PHARMA S.A.-25.88%171
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156